Procter & Gamble
PG
$161.57
+0.61%
Procter & Gamble is one of the world's largest consumer staples manufacturers, operating a portfolio of more than 20 billion-dollar brands — including Tide, Pampers, Charmin, Pantene, and Gillette — across five reportable segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care, with roughly half of consolidated sales generated outside the United States. The company's competitive identity rests on scale-driven cost advantages, category-leading shelf share, and pricing power built over nearly two centuries, making it a bellwether holding for defensive and dividend-oriented portfolios rather than a growth vehicle. The current investor debate centers on whether P&G can return to positive volume growth after several years of price-led revenue expansion, with fiscal 2027 guidance landing below consensus on roughly $1.36 billion of cost headwinds and margin pressure from input and tariff-related inflation. That tension — accelerating top-line trends against a compressed margin outlook and a stock that has recently rallied hard — frames the central question of whether the recent move reflects genuine fundamental inflection or an overextended defensive rotation.…
PG
Procter & Gamble
$161.57
Related headlines
Investment Opinion: Should I buy PG Today?
Rating: Hold. PG is a high-quality defensive compounder with a 2.88% dividend yield and a 29.5% ROE, but the current price of $161.02 offers limited upside given the analyst average target of $168.87 (+4.9%) and the stock's 9.25% one-month rally into resistance. The core thesis is that margin compression and lack of volume growth offset the safety of the franchise, leaving the risk/reward balanced.
Supporting evidence: The stock trades at 21.7x trailing and forward earnings, a mid-range multiple historically but with a PEG of 18.1 that highlights the absence of growth. Revenue growth decelerated to 1.5% in Q4 from 3.0% in Q1, and net margin fell to 14.1% from 21.2% over the same period. Free cash flow of $15.91 billion covers the dividend (payout ratio 63.8%) but offers a thin 4.5% FCF yield. The analyst consensus is 'buy' with a mean rating of 2.16, but the average target implies only 4.9% upside, and recent downgrades from Argus and HSBC suggest fading enthusiasm.
Risks and conditions: The biggest risks are continued margin compression, failure to achieve volume growth, and a rotation out of defensive stocks. This Hold would upgrade to Buy if PG's PE compresses below 19x (around $140) or if volume growth turns positive and margins stabilize. It would downgrade to Sell if revenue growth turns negative or if operating margins fall below 18% sustainably. Relative to its own history (PE band 19.2x–31.3x) and peers, PG is fairly valued, not cheap, and the recent rally has removed the margin of safety.
Sign up to view all
PG 12-Month Price Forecast
PG is a high-quality defensive name but faces a challenging near-term outlook with margin compression and weak volume growth. The stock's recent rally has pushed it to near resistance with limited margin of safety, and the valuation offers no growth support. The analyst consensus is constructive but implies modest upside, and recent downgrades suggest caution. We would upgrade to bullish if volume growth turns positive and margins stabilize, or if the price pulls back to ~$140 providing a better entry point. We would downgrade to bearish if revenue growth turns negative or if operating margins fall below 18%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Procter & Gamble's 12-month outlook, with a consensus price target around $173.65 and implied upside of +7.5% versus the current price.
Average Target
$173.65
0 analysts
Implied Upside
+7.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$151 - $190
Analyst target range
Coverage is deep and institutional, with 23 analysts following PG and a consensus recommendation of "buy" (mean rating of 2.16 on a scale where lower is more bullish). The average target price of $168.87 implies roughly +4.9% upside from the current $161.02, a modest return that is roughly in line with the 2.88% dividend yield and suggests the consensus sees limited near-term price appreciation after the recent rally. Sentiment leans cautiously constructive rather than aggressively bullish: the consensus EPS estimate of $7.37 and revenue estimate of $94.16 billion imply low-single-digit growth, and the modest implied upside indicates analysts believe the stock is fairly valued after its 9.2% one-month surge.
The target range of $143.00 to $190.00 is wide — a 33% spread from low to high — signaling genuine disagreement about the margin trajectory. The $190 high target likely assumes successful volume reacceleration, cost headwind absorption, and multiple expansion back toward the 25x+ levels seen in 2023–2024, while the $143 low target (below the current price) prices in continued margin compression, weak volumes, and a de-rating toward the low end of the historical PE band. Recent rating actions skew mildly negative: Argus downgraded to Hold from Buy in August 2026 and HSBC moved to Hold from Buy in July, even as Citigroup, BofA, JPMorgan, and Wells Fargo maintained Buy/Overweight ratings — a pattern of fading enthusiasm that aligns with the stock's rally into resistance and the cautious tone of recent coverage questioning whether there is margin of safety at current levels.
Bulls vs Bears: PG Investment Factors
The bear case currently has stronger evidence: margin compression is severe and accelerating (Q4 net margin of 14.1% vs. 21.2% in Q1), volume growth is absent, and the stock has rallied to near resistance with a PEG of 18.1 that offers no valuation cushion. The bull case rests on defensive rotation, brand strength, and cash flow, but these are already reflected in a 21.7x PE that is mid-range historically. The single most important tension is whether P&G can return to positive volume growth to offset cost inflation and stabilize margins; without that, the recent rally looks like an overextended defensive trade rather than a fundamental inflection. A resolution of this tension—either through volume acceleration or a price pullback to ~$130—would materially change the thesis.
Bullish
- Defensive rotation driving strong momentum: PG has surged 9.25% in the past month versus SPY's -1.02%, a +10.27 percentage point relative strength swing that signals a powerful rotation into consumer staples. Year-to-date gains of 13.56% and a 6-month return of 8.67% confirm the stock is in a recovery-to-uptrend phase, with the recent thrust concentrated in the last quarter.
- Premium profitability and returns: Full-year gross margin of 50.2% and operating margin of 22.7% remain well above household products peers, while ROE of 29.5% and ROA of 10.4% demonstrate exceptional capital efficiency. These metrics underpin the company's ability to generate consistent cash flow and support its dividend.
- Solid free cash flow and dividend coverage: Trailing free cash flow of $15.91 billion comfortably covers $2.61 billion in quarterly dividends and $875 million in buybacks, with a payout ratio of 63.8%. The 2.88% dividend yield provides a meaningful total-return component, especially if price appreciation moderates.
- Analyst consensus remains constructive: 23 analysts rate PG a 'buy' with a mean rating of 2.16 and an average target price of $168.87, implying +4.9% upside from $161.02. The high target of $190 suggests some analysts see potential for multiple expansion if volume growth returns.
Bearish
- Margin compression accelerating: Net margin fell from 21.2% in Q1 to 14.1% in Q4, while gross margin slid from 51.4% to 48.5% and operating margin from 26.2% to 18.6%. EBITDA collapsed to $1.82 billion in Q4 from $6.99 billion in Q1, reflecting $1.36 billion in cost headwinds and input inflation.
- Volume growth remains elusive: Revenue grew just 1.5% year-over-year in Q4 to $21.20 billion, decelerating from 3.0% in Q1, as pricing rather than volume has carried the top line. Consensus forward revenue of $94.16 billion implies only low-single-digit growth, well below what is needed to justify multiple expansion.
- Valuation lacks growth support: The PEG ratio of 18.1 is a stark warning that the 21.7x PE is not supported by earnings growth. The flat PE curve (21.72x trailing vs. 21.75x forward) implies the market expects almost no EPS growth over the next twelve months, capping upside unless volumes inflect.
- Recent rally leaves little margin of safety: After a 9.25% one-month surge, PG sits at 79% of its 52-week range and just 3.9% below the $167.25 high. The -2.76% single-day drop on elevated volume of 10.33 million shares suggests profit-taking and potential short-term exhaustion, with limited room before overhead resistance.
PG Technical Analysis
PG is in a recovery-to-uptrend phase rather than a clean secular advance: the stock is up 5.79% over the trailing year but has decisively outperformed recently, with year-to-date gains of 13.56% and a 6-month return of 8.67%. At $161.02, the shares sit at roughly 79% of the 52-week range bounded by a $137.62 low and a $167.25 high — a positioning that signals momentum leadership but also leaves limited room before overhead resistance, and the trailing 1-year relative strength versus SPY of -7.34 confirms the stock lagged the market for much of the past twelve months before this recent surge. The maximum drawdown of -16.15% over the period underscores that this is a defensive name capable of meaningful mark-to-market pain when sentiment shifts.
Short-term momentum is unambiguously accelerating and diverging positively from the longer-term trend: the 1-month change of +9.25% and 3-month change of +9.23% are nearly identical, indicating a sharp, sustained thrust concentrated in the last quarter rather than a one-off spike. Critically, PG's 1-month relative strength versus SPY is +10.27 percentage points (versus SPY's -1.02%), a massive rotation signal into consumer staples that contrasts with the stock's -7.34% 1-year relative strength — a classic mean-reversion catch-up pattern. The most recent session, however, showed a -2.76% pullback from a $165.59 close to $161.02 on elevated volume of 10.33 million shares, suggesting profit-taking at the highs and a potential short-term exhaustion signal after the run to $165.59, which itself sits just below the $167.25 52-week high.
Key technical levels are well defined: resistance sits at the $167.25 52-week high, with the $165.59 recent peak acting as an immediate ceiling, while support is anchored at the $137.62 52-week low with intermediate support likely in the $150–153 zone where the stock consolidated in early October. A breakout above $167.25 on volume would confirm a new leg higher and likely trigger momentum-fund accumulation, whereas a breakdown below $150 would suggest the recent rally was a failed breakout and refocus attention on the $137.62 floor. With a short ratio of 2.98 (roughly three days of average volume to cover shorts), bearish positioning is modest and not a major squeeze catalyst; volatility is comparatively contained for a mega-cap staple, but the -2.76% single-day drop on above-average volume argues for disciplined position sizing and stop placement rather than chasing strength at current levels.
Beta
0.38
0.38x market volatility
Max Drawdown
-16.1%
Largest decline past year
52-Week Range
$138-$167
Price range past year
Annual Return
+8.0%
Cumulative gain past year
| Period | PG Return | S&P 500 |
|---|---|---|
| 1m | +11.2% | -0.9% |
| 3m | +11.8% | +1.2% |
| 6m | +9.7% | +4.9% |
| 1y | +8.0% | +11.2% |
| ytd | +14.0% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PG Fundamental Analysis
Revenue is growing but only modestly, and the trajectory is decelerating at the margin: fiscal Q4 2026 revenue of $21.20 billion grew just 1.5% year-over-year, a slowdown from the $22.21 billion (+1.5% vs. $21.88 billion) posted in Q2 and the $22.39 billion (+3.0% vs. $21.74 billion) in Q1, while Q3 revenue of $21.24 billion rose 7.4% against a soft $19.78 billion comparable. The segment mix shows Fabric & Home Care as the largest contributor at $7.43 billion, followed by Baby/Feminine/Family Care at $5.05 billion, Beauty at $3.98 billion, Health Care at $2.76 billion, and Grooming at $1.70 billion — a portfolio skewed toward mature, low-growth categories where pricing, not volume, has carried the top line. The implication for the investment case is that P&G needs volume reacceleration to justify multiple expansion; consensus revenue of $94.16 billion for the forward year implies only low-single-digit growth, consistent with a staples compounder rather than a re-rating story.
Profitability remains robust in absolute terms but is compressing: Q4 2026 net income of $3.00 billion produced a 14.1% net margin, down sharply from 18.7% in Q3, 19.5% in Q2, and 21.2% in Q1, while gross margin slid from 51.4% in Q1 to 49.5% in Q3 and 48.5% in Q4. Operating margin followed the same path, falling from 26.2% in Q1 to 21.5% in Q3 and just 18.6% in Q4, and EBITDA collapsed to $1.82 billion in Q4 from $6.99 billion in Q1 — a deterioration that reflects the cost headwinds management flagged in its below-consensus fiscal 2027 guidance. The full-year gross margin of 50.2% and operating margin of 22.7% remain healthy for household products and above many peers, but the direction of travel is negative, and the 18.4% trailing net margin masks a fourth quarter that annualizes closer to 14%. Until volume growth offsets cost inflation, margin recovery is the key swing factor for earnings revisions.
Balance sheet and cash generation are solid but not fortress-like: debt-to-equity of 0.64 is moderate for a staples issuer, though the current ratio of 0.68 reflects P&G's deliberately lean working capital model (negative cash conversion cycle of -41.4 days) rather than distress. Trailing free cash flow of $15.91 billion comfortably covers the $2.61 billion in quarterly dividends and $875 million of buybacks, with a dividend payout ratio of 63.8% and a 2.88% yield that remains the core of the total-return case. ROE of 29.5% is exceptional and ROA of 10.4% is respectable, but the FCF yield of roughly 4.5% ($15.91 billion against a $355 billion market cap) is thin for a low-growth business, and the 5.8x interest coverage in Q4 (versus 20x+ in prior quarters) bears watching if rates stay elevated.
Quarterly Revenue
$21.2B
2026-06
Revenue YoY Growth
+1.5%
YoY Comparison
Gross Margin
48.5%
Latest Quarter
Free Cash Flow
$15.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PG Overvalued?
Because P&G is solidly profitable (Q4 net income of $3.00 billion; trailing EPS positive), the PE ratio is the appropriate primary metric. The stock trades at 21.72x trailing earnings and 21.75x forward earnings — an essentially flat curve that implies the market is pricing in almost no earnings growth over the next twelve months, consistent with consensus EPS of $7.37 against a current price of $161.02. The PEG ratio of 18.1 is a stark warning that the multiple is not supported by growth, and the 4.08x PS and 15.58x EV/EBITDA multiples confirm a premium-quality, low-growth profile rather than a value opportunity.
Against the household & personal products industry, PG's 21.7x PE and 4.08x PS represent a meaningful premium — roughly in line to modestly above the sector's typical high-teens to low-20s earnings multiple, and a clear premium on sales given P&G's 50.2% gross margin versus the mid-30s to low-40s typical of the group. The premium is defensible on brand strength, 29.5% ROE, and a 2.88% dividend yield, but the 18.1 PEG and 6.54x price-to-book (versus a historical band of roughly 6.4x–8.8x) suggest the market is paying for quality without getting growth — a combination that historically caps upside unless volumes inflect.
Historically, PG's PE has ranged from roughly 19.2x to 31.3x over the past several years, with the current 21.7x sitting in the lower-middle of that band and well below the 26x–29x levels seen in 2023–2024. On price-to-sales, however, the current 4.08x is near the low end of its own history (versus 15.6x–20.2x on a quarterly basis in the historical ratio series), reflecting the recent compression in margins and the market's skepticism about the earnings base. The read-through is nuanced: the stock is not expensive relative to its own earnings history, but it is not cheap either, and the combination of a mid-band PE with deteriorating margins suggests the market has already priced in much of the near-term bad news — leaving the risk/reward balanced rather than compelling at $161.
PE
21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are mounting as margins compress across all levels. Net margin fell from 21.2% in Q1 to 14.1% in Q4, gross margin from 51.4% to 48.5%, and operating margin from 26.2% to 18.6%, while EBITDA collapsed to $1.82 billion in Q4 from $6.99 billion in Q1. The company faces $1.36 billion in cost headwinds for fiscal 2027, and revenue growth of just 1.5% in Q4 (down from 3.0% in Q1) shows limited ability to offset these pressures through pricing. Additionally, the current ratio of 0.68, while reflective of a lean working capital model, leaves little buffer if input costs spike further. Interest coverage fell to 5.8x in Q4 from over 20x in prior quarters, a potential concern if rates remain elevated.
Market and competitive risks center on valuation compression and sector rotation. PG trades at 21.7x trailing and forward earnings, with a PEG of 18.1 that signals the market is paying for quality without growth. The stock's beta is not provided, but its 1-year relative strength versus SPY is -7.34%, indicating it lagged the market for much of the past year before the recent surge. A rotation back into growth stocks—highlighted by recent news of the 'Magnificent Seven' trade fracturing—could reverse the defensive flows that drove the 9.25% one-month gain. Competitive threats from private-label brands and evolving consumer preferences, particularly in developed markets, could pressure market share. Regulatory headwinds, such as potential tariffs or environmental regulations, add another layer of uncertainty.
Worst-case scenario: A combination of persistent volume stagnation, escalating cost inflation, and a market rotation out of staples could drive PG back to its 52-week low of $137.62, representing a -14.5% decline from $161.02. If margin compression continues and the stock de-rates toward the low end of its historical PE band (19.2x), the downside could extend to the analyst low target of $143.00 (-11.2%). A more severe scenario, such as a recession that hits consumer spending and triggers dividend concerns, could push the stock below $130, a -19.3% drop. The maximum drawdown over the past period was -16.15%, underscoring that even defensive names can experience meaningful mark-to-market pain.
FAQ
The most severe risk is margin compression: net margin fell to 14.1% in Q4 from 21.2% in Q1, and EBITDA collapsed to $1.82 billion from $6.99 billion, with $1.36 billion in cost headwinds expected for fiscal 2027. Second, volume growth is absent, with revenue growth decelerating to 1.5% in Q4, leaving the company reliant on pricing that may not be sustainable. Third, valuation risk: a PEG of 18.1 and a 21.7x PE offer no cushion if growth disappoints, and a rotation out of defensive stocks could drive the stock toward its 52-week low of $137.62. Finally, competitive and regulatory risks, including private-label competition and potential tariffs, could further pressure margins.
Our 12-month forecast has a base case (55% probability) of $160–$175, assuming low-single-digit revenue growth and margin stabilization, with the stock trading around the analyst average target of $168.87. The bull case (25% probability) targets $175–$190 if volume growth returns and multiples expand toward 25x, while the bear case (20% probability) targets $137–$150 if margins compress further and defensive rotation reverses. The most likely scenario is the base case, hinging on PG's ability to offset cost headwinds through pricing and modest volume recovery. Key catalysts include the next earnings report and any commentary on fiscal 2027 guidance.
PG trades at 21.7x trailing and forward earnings, which is in the middle of its historical PE band of 19.2x to 31.3x, suggesting it is fairly valued relative to its own history. However, the PEG ratio of 18.1 and a PS ratio of 4.08 indicate the market is paying a premium for quality without growth. Compared to the household products industry, PG's PE is in line to modestly above the sector's high-teens to low-20s multiple, but its 50.2% gross margin justifies some premium. The flat PE curve implies the market expects almost no earnings growth, so the stock is neither overvalued nor undervalued—it is priced for perfection in a low-growth environment.
PG is a high-quality defensive stock, but at $161.02 it offers limited upside with an average analyst target of $168.87 (+4.9%) and a PEG ratio of 18.1 that signals the valuation is not supported by growth. The recent 9.25% one-month rally has pushed the stock near resistance at $167.25, leaving little margin of safety. The biggest downside risk is a return to the 52-week low of $137.62, a -14.5% decline, if margin compression continues. For long-term income investors, PG can be a core holding, but waiting for a pullback to ~$140 would provide a better entry point. It is not a compelling buy at current levels for growth-oriented investors.
PG is best suited for long-term investment, given its stable dividend (2.88% yield), low volatility relative to growth stocks, and consistent cash flow generation. The stock's beta is not provided, but its defensive nature and 63.8% payout ratio make it a reliable income vehicle. Short-term trading is less attractive due to the recent rally into resistance and the potential for profit-taking, as evidenced by the -2.76% single-day drop on elevated volume. A minimum holding period of 3-5 years is recommended to capture the dividend and potential modest capital appreciation, while short-term traders should wait for a pullback to support levels around $150 or $140.